Neoplasia and Chronic Disease Associated With the Prolonged Administration of Dehydroheliotridine to Rats

When dehydroheliotridine (DHH), a pyrrolizidine alkaloid metabolite with bifunctional alkylating and antimitotic activities, was administered to a hooded strain of rats by ip injection, the incidence of tumors, excluding interstitial cell tumors, was significantly greater than that in saline-injecte...

Full description

Saved in:
Bibliographic Details
Published in:JNCI : Journal of the National Cancer Institute 1983-02, Vol.70 (2), p.381-386
Main Authors: Peterson, John E., Jago, Marjorie V., Reddy, Janardan K., Jarrett, Richard G.
Format: Article
Language:English
Subjects:
Age Factors
Animals
Body Weight
Injections, Intraperitoneal
Liver - drug effects
Lung - drug effects
Monocrotaline - analogs & derivatives
Neoplasms, Experimental - chemically induced
Pyrrolizidine Alkaloids - toxicity
Rats
Thioacetamide - pharmacology
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:When dehydroheliotridine (DHH), a pyrrolizidine alkaloid metabolite with bifunctional alkylating and antimitotic activities, was administered to a hooded strain of rats by ip injection, the incidence of tumors, excluding interstitial cell tumors, was significantly greater than that in saline-injected controls. The number of tumors was not further increased when thioacetamide (TA) was co-administered for its mitosis-stimulating effect. The life-span of the rats was significantly shortened by DHH and more so by combined DHH and TA treatment, but not by TA alone. The results indicate that DHH is responsible for some, possibly most, of the carcinogenicity of the parent pyrrolizidine alkaloids and also stimulates the earlier and more rapid development of renal and vascular diseases normally associated with aging in rats.
ISSN:0027-8874
1460-2105
DOI:10.1093/jnci/70.2.381